Factory 99% Dotinurad Powder CAS 1285572-51-1 Chemical Intermediate Dotinurad

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A990
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Dotinurad
• CAS: 1285572-51-1
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Dotinurad
Appearance	White Powder
CAS NO.	1285572-51-1
Storage	Keep in a cool, dry, dark location

 

Dotinurad (brand name: Uricen®) is a selective urate transporter 1 (URAT1) inhibitor developed for the management of hyperuricemia and gout. It functions by blocking URAT1-mediated reabsorption of uric acid in the renal proximal tubules, thereby increasing urinary excretion of uric acid and lowering serum uric acid levels. Structurally distinct from other URAT1 inhibitors, Dotinurad exhibits high specificity and minimal interaction with other renal transporters, enhancing its safety profile.

 

1. Hyperuricemia Treatment: Reduces elevated serum uric acid concentrations to target levels (e.g., <6.0 mg/dL), addressing the primary risk factor for gout and urate nephropathy.
2. Gout Prevention: Mitigates gout flare frequency and severity by inhibiting monosodium urate crystal deposition in joints and soft tissues.
3. Chronic Kidney Disease (CKD) Management: Improves renal function by reducing uric acid-induced oxidative stress and inflammation, potentially slowing CKD progression.

1. Selective URAT1 Inhibition: Blocks uric acid reabsorption without affecting other renal transporters (e.g., GLUT9, ABCG2), minimizing adverse effects.
2. Uric Acid Excretion Enhancement: Increases fractional excretion of uric acid (FEUA) by up to 30%, facilitating rapid normalization of serum uric acid levels.
3. Safety and Tolerability: Demonstrates low rates of adverse events (e.g., gastrointestinal discomfort, liver enzyme elevations) in clinical trials, with no significant drug-drug interactions.